Italian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 receptor agonist from China’s Gan & Lee Pharmaceuticals dosed once every two weeks, for €62 million upfront, up to €664 million in milestones, and “double-digit” royalties. Menarini will handle regulatory submissions and commercialization across 39 European markets.
Denmark’s Novo Nordisk has signed a collaboration with Boston-based Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated metabolic diseases. Vivtex is eligible to receive upfront payments, research funding and milestone payments totalling up to $2.1 billion (approximately €1.78bn), as well as tiered royalties on net sales of any resulting products.